Skip to main content
UHS logo

UHS · Universal Health Services Inc

Track UHS — free
Market Cap
$10.30B
Shares
58.94M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$174.83 Open$174.11 Day$173.35–177.00 52W close$141.17–244.18 Avg vol 30d672K Short int2.6M · 4.4% float · 4.0d Short vol71% Last earningsJul 28, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 7

Up next

Next earnings call
Oct 27, 2026 Est · unconfirmed · in 6 wks
filed Aug 7, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$18.11B
Trailing 12 months
Net income (TTM)
$1.53B
Trailing 12 months
Revenue growth YoY
+8.3%
Year over year
Operating margin
11.4%
Trailing 12 months
P / E (TTM)
7.1
Trailing earnings · reciprocal yield 14.0%
FCF yield
8.2%
TTM · current market cap
Return on invested capital
12.9%
Trailing 12 months
Net cash
−$4.71B
Latest balance sheet
Dividend yield
0.5%
Trailing 12 months
Shares change YoY
-7.8%
Year over year · fewer shares
Price change (1Y)
-8.4%
Trailing year
Short interest
4.4%
Latest settlement · 4.0 days to cover
View all 115 metrics

AI Brief

Q2 FY26 earnings call · Jul 28, 2026
Q2 FY26

TL;DR. UHS reported Q2 adjusted EPS of $5.98 (+12% YoY) and adjusted EBITDA less NCI of $678 million (+5% YoY), but lowered full-year 2026 adjusted EBITDA guidance by approximately $50 million at the midpoint to a range of $2.61–$2.72 billion due to higher professional/general liability reserves, elevated losses at the San Antonio behavioral facility and Cedar Hill, and lower volume assumptions, partially offset by an unbudgeted $100 million Florida DPP benefit.

Bullish
  • + Q2 included an unbudgeted $100 million favorable Florida Medicaid DPP benefit that was not in original guidance.
  • + Added 177 licensed beds (2.5% increase to same-facility acute care bed capacity) including opening the Allen B. Miller Medical Center.
  • + Share repurchases accelerated to $320 million in Q2 from $127 million in Q1, with $978 million remaining authorization.
  • + Pending Talkspace acquisition expected to close mid-August 2026, creating a national end-to-end behavioral health continuum.
Bearish
  • UHS lowered 2026 adjusted EBITDA less NCI guidance by about $50 million at the midpoint to $2.61–$2.72 billion (1.9% decrease at midpoint).
  • Increased professional and general liability reserves added $28 million pre-tax in Q2 and ~$50 million for full-year 2026.
  • San Antonio behavioral hospital lost certification, incurring $10 million pre-tax loss in Q2 and expected $5–10 million quarterly losses through year-end.
  • Cedar Hill (Washington D.C.) de novo ramping slower than expected; tailwind reduced from $50 million to $20 million, now expected to reach break-even only in Q4.
  • Lowered full-year same-facility volume guidance: acute care admissions to 1.5–2.5% and behavioral health patient days to 1.0–2.0%.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bearish Fundamentals Excellent Quant / Vol High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −5%
below
Price vs 50-day avg +6%
above
RSI (14) 57
neutral
MACD trend Negative
52-week position 33%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +2%
trailing
6-month return −6%
trailing
YTD return −20%
this year
Relative strength −24%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $165 › 200d $185 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +69 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.37% of float · ▲ +0.4% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
598 holders — mid 3-yr range
Squeeze score 61
elevated · 0–100
Fundamentals
Excellent
Revenue growth +10%
Y/Y
EPS growth +37%
Y/Y
Free cash flow $849.2M
Valuation P/E 7.1
below peers
Buyback $1.4B
remaining
Balance sheet $4.6B
net debt
Quant / Vol
risk profile
High
Volatility 32%
annualized · 1-yr
Max drawdown −42%
past year
ATR 3.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Jul 28, 2026
For the Year Ended December 31, 2026
Net revenues Initiated $18.5B – $18.76B
prior FY $17.36B midpoint +7.3% Y/Y
Adjusted EPS – diluted Initiated $22.28 – $23.65
Adjusted EBITDA, net of NCI Initiated $2.61B – $2.72B
full year of 2026
Capital expenditures Initiated $950M – $1.1B
Prior guidance period ended · from the 8-K filed Jul 25, 2024
Net revenues · For the Year Ended December 31, 2024 $15.57B – $15.75B
Adjusted EPS – diluted · For the Year Ended December 31, 2024 $15.40 – $16.20
Adjusted EBITDA, net of NCI · For the Year Ended December 31, 2024 $2.15B – $2.23B
Guided vs delivered · last 1 settled
Net revenues For the Year Ended December 31, 2024
guided $15.57B – $15.75B
$15.83B Beat +1.1%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−5% Bearish
Price vs 50-day avg
+6% Bullish
RSI (14)
57 Neutral
MACD trend
Negative Bearish
52-week position
33% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $165 › 200d $185 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +69 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.37% of float · ▲ +0.4% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
598 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $141 Now $175 · 33% Range high $244
vs 200-day avg -5% vs 50-day avg +6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
UHS
Universal Health Services Inc
this stock
$10.30B -19.8% +9.7% 7.1 4.4%
HCA
HCA Healthcare, Inc.
$94.71B -8.6% +7.1% 14.7 2.8%
FSNUY
Fresenius SE & Co. KGaA
$29.49B -8.7% 0.0%
THC
Tenet Healthcare Corp
$21.23B +32.7% +0.9% 10.2 2.3%
EHC
Encompass Health Corp
$12.01B +14.7% +10.5% 19.8 3.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
598
% held
89.4%
Net QoQ
+851.5K sh
Top holder
First Eagle Investment Ma…
Held Float
View
Held by Funds
Fund positions
643
View
Short & Settlement
Short Interest Rising
Shares short
2.6M
Days to cover
4.0d
Change
+10.9K sh
View
Short Volume
Short vol %
71%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
45.7K
Value
$7.9M
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
38.6%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 27, 2026
View
Financials
Financials
Revenue (FY)
$17.4B
Net income (FY)
$1.5B
EPS diluted
$23.10
View
Buybacks
Authorized · 3 programs
$5.0B
Remaining
$1.4B
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 21, 2026
This year
18
View
Proposed Sales
Value
$68.8K
Shares
356
Filed
Mar 13, 2026
View
Earnings & Events
Earnings Calls
Last call
Jul 28, 2026
View

Performance

5D 20D 120D MTD YTD
UHS +3.3% +2.1% -5.9% +2.6% -19.8%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY +4.5% +3.9% -23.8% +3.0% -31.9%

Capital returns

Latest dividend
$0.20 / share · ex Sep 1, 2026
Paid (TTM)
$0.80 / share · 4 payouts
Dividend yield (TTM, derived)
0.46%
Buyback programs · 3 active · as of Dec 31, 2025
Authorized (total)
$5.00B
Spent (derived)
$3.60B
Remaining
$1.40B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 352915 CUSIP 913903100 13F (30d) 149 filings 147 filers Visit website Investor relations